Anixa Biosciences, Inc. (FRA:CY71)
Germany · Delayed Price · Currency is EUR | Market Cap | 130.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.72M |
| Shares Out | n/a |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,779 |
| Average Volume | 484 |
| Open | 3.880 |
| Previous Close | 3.960 |
| Day's Range | 3.880 - 3.980 |
| 52-Week Range | 2.040 - 4.300 |
| Beta | n/a |
| RSI | 62.22 |
| Earnings Date | Jan 9, 2026 |
About Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the develo... [Read more]
News
Anixa Biosciences, Inc. (ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs Transcript
Anixa Biosciences, Inc. ( ANIX) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs November 11, 2025 2:00 PM EST Company Participants Amit Kumar - CEO, Chairman & Co-C...
Anixa Biosciences (ANIX) Unveils New Name for Ovarian Cancer Therapy
Anixa Biosciences (ANIX) Unveils New Name for Ovarian Cancer Therapy
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
SAN JOSE, Calif. , Nov. 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences: Hard To Justify The Market's Optimism With An Upcoming Phase 1 Readout
Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat
Water Tower Research (WTR) issued the following statement regarding a technical issue that occurred during its recent Fireside Chat with Anixa Biosciences, Inc. (NASDAQ: ANIX), held on Tuesday, Novemb...
Anixa Biosciences (ANIX) Secures U.S. Patent for Breast Cancer Vaccine
Anixa Biosciences (ANIX) Secures U.S. Patent for Breast Cancer Vaccine
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026 SAN JOSE, Calif. , Nov. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" o...
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
SAN JOSE, Calif. , Nov. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences executes data transfer deal with Cleveland Clinic
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
Completion of key step in IND transfer for upcoming Phase 2 breast cancer vaccine clinical trial SAN JOSE, Calif. , Nov. 5, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NAS...
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
SAN JOSE, Calif. , Oct. 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine in China
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine in China
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
Expands global intellectual property coverage in markets with high breast cancer incidence New patent will provide IP protection of Breast Cancer Vaccine in China into 2040 SAN JOSE, Calif. , Oct. 20,...
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
Final Clinical Visit Marks Major Milestone in First-in-Human Evaluation of Breast Cancer Vaccine Comprehensive Immune Response and Safety Data to Be Presented at the San Antonio Breast Cancer Symposiu...
Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention Comprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Di...
Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity SAN JOSE, Calif. , Sept. 8, 2025 /PRNewswire/ -- A...
Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
SAN JOSE, Calif. , Sept. 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN JOSE, Calif. , Aug. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with high breast cancer incidence New patent will pr...
Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif. , Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ...
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif. , Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: AN...
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference
Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer SAN JOSE, Calif. , Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a bi...
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial
Progress Follows Positive Immune Response Observed in Phase 1 Study SAN JOSE, Calif. , Aug. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c...
Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology
Patent Strengthens International Protection for First-of-Its-Kind Immunopreventive Platform Expands Global IP Coverage in Markets with High Incidence of Breast Cancer SAN JOSE, Calif. , July 30, 2025 ...
Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s
Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine Platform Technology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market Potential SAN JOSE, Cali...